![Douglas Eby](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Relazioni attive
Nome | Sesso | Età | Società collegate | Collaborazione |
---|---|---|---|---|
James Francis Winschel | M | 75 |
Cambridge Science Corp.
![]() Cambridge Science Corp. BiotechnologyHealth Technology Cambridge Science Corp. engages in investing in the medicine. It also engages in improving patient lives through the acceleration of translational research and develops internal drug development programs. The firm finances and manages biotech companies commercializing novel technologies developed in the labs and the research institutions. The company was founded in 2017 and is headquartered in Cambridge, MA. | - |
William David Stovin | M | 62 |
KYTTARO Ltd.
![]() KYTTARO Ltd. BiotechnologyHealth Technology Kyttaro Ltd. develops monoclonal antibodies for potential treatment of atherosclerotic cardiovascular diseases. The company is based in Oxford, UK. The British company was founded in 2021. The CEO is Douglas Eby. | - |
Irene Chong | F | - |
Cambridge Science Corp.
![]() Cambridge Science Corp. BiotechnologyHealth Technology Cambridge Science Corp. engages in investing in the medicine. It also engages in improving patient lives through the acceleration of translational research and develops internal drug development programs. The firm finances and manages biotech companies commercializing novel technologies developed in the labs and the research institutions. The company was founded in 2017 and is headquartered in Cambridge, MA. | - |
Charanjit Bountra | M | 63 |
KYTTARO Ltd.
![]() KYTTARO Ltd. BiotechnologyHealth Technology Kyttaro Ltd. develops monoclonal antibodies for potential treatment of atherosclerotic cardiovascular diseases. The company is based in Oxford, UK. The British company was founded in 2021. The CEO is Douglas Eby. | 3 anni |
Gary Steinberg | M | 72 |
Cambridge Science Corp.
![]() Cambridge Science Corp. BiotechnologyHealth Technology Cambridge Science Corp. engages in investing in the medicine. It also engages in improving patient lives through the acceleration of translational research and develops internal drug development programs. The firm finances and manages biotech companies commercializing novel technologies developed in the labs and the research institutions. The company was founded in 2017 and is headquartered in Cambridge, MA. | - |
Scott Wasserman | M | 54 |
KYTTARO Ltd.
![]() KYTTARO Ltd. BiotechnologyHealth Technology Kyttaro Ltd. develops monoclonal antibodies for potential treatment of atherosclerotic cardiovascular diseases. The company is based in Oxford, UK. The British company was founded in 2021. The CEO is Douglas Eby. | 2 anni |
Grafico relazionale
Relazione in diverse aziende
Statistiche
Paese | Relazioni | % del totale |
---|---|---|
Regno Unito | 3 | 50.00% |
Stati Uniti | 3 | 50.00% |
Età delle relazioni
Attive
Scorse
Uomo
Donna
Amministratori
Dirigenti
Provenienza delle relazioni
- Borsa valori
- Insiders
- Douglas Eby
- Contatti personali